Clinical Immunology Direction, Center of Molecular Immunology, Havana, Cuba.
Hermanos Ameijeiras Hospital, Havana, Cuba.
Semin Oncol. 2018 Jan;45(1-2):34-40. doi: 10.1053/j.seminoncol.2018.04.009. Epub 2018 May 1.
Lung cancer remains one of the leading causes of cancer-related deaths. Non-small cell lung cancer (NSCLC) is the most common histologic type of lung cancer. Medical and scientific progress has led to longer survival in an increasing number of patients suffering from cancer. Concerning patients with advanced NSCLC, there is a subgroup with long-term survival. The human epidermal growth factor receptor (EGFR) family plays a key role in tumor development. This cluster of genes is associated with augmented angiogenesis and enhanced proliferation, survival, and migration of tumor cells. The CIMAvax-EGF vaccine consists of a chemical conjugate of the EGF with the P64 protein derived from the Meningitis B bacteria and the Montanide ISA 51, as adjuvant. The vaccine induces antibodies against EGF that results in EGF withdrawal. CIMAvax-EGF has been demonstrated to be safe and immunogenic in advanced NSCLC patients. Here we summarize the current knowledge of the mechanism of action of CIMAvax-EGF, highlighting the impact of this anti-EGF-based vaccine on the long-term survival of advanced NSCLC patients.
肺癌仍然是癌症相关死亡的主要原因之一。非小细胞肺癌（NSCLC）是最常见的肺癌组织学类型。医学和科学的进步使得越来越多的癌症患者的生存时间延长。对于晚期 NSCLC 患者，存在一个长期生存的亚组。人类表皮生长因子受体（EGFR）家族在肿瘤的发展中起着关键作用。这组基因与血管生成的增强以及肿瘤细胞的增殖、存活和迁移有关。CIMAvax-EGF 疫苗由 EGF 与源自脑膜炎 B 细菌的 P64 蛋白的化学缀合物以及 Montanide ISA 51 组成，作为佐剂。该疫苗诱导针对 EGF 的抗体，导致 EGF 耗竭。CIMAvax-EGF 已被证明在晚期 NSCLC 患者中是安全且具有免疫原性的。在这里，我们总结了 CIMAvax-EGF 的作用机制的现有知识，强调了这种基于抗 EGF 的疫苗对晚期 NSCLC 患者长期生存的影响。
